At LuMind IDSC Foundation, we accelerate research to increase availability of therapeutic, diagnostic, and medical care options and we empower families through education, connections, and support.
LIFE-DSR - A National Launch for the First Natural History Study in Adults with Down Syndrome
Dr. James Hendrix, LuMind IDSC Chief Scientific Officer, discusses the launch of the LIFE-DSR (Longitudinal Investigation for Enhancing Down Syndrome Research) study in the attached blog post. This is a first for LuMind IDSC and represents an important milestone for Down syndrome research. The LIFE-DSR study will be the first study run in LuMind’s DS-CTN (Down Syndrome – Clinical Trials Network) which includes 11 research sites in 9 states.

Read more here: https://www.lumindrds.org/life-dsr-study/

Ready to learn even more and ask Dr. Hendrix questions? Great! Join our webinar, LIFE-DSR - A National Launch for the First Natural History Study in Adults with Down Syndrome, where you will learn why LuMind IDSC is launching the first natural history study for adults with Down syndrome and why this is a game changer for Down syndrome clinical trials.

May 30, 2019 4:30 PM in Eastern Time (US and Canada)

LuMind IDSC logo
* Required information
Loading

Speakers

James Hendrix, Ph.D.
Chief Scientific Officer @LuMind IDSC Foundation
Prior to joining LuMind, Dr. Hendrix was director, global science initiatives, at the Alzheimer’s Association. As a member of the Medical and Scientific Relations Division, he provided leadership on specific domestic and international efforts focused on advancing the division’s science agenda. A critical element of his role is to manage industry consortia such as the Alzheimer’s Association Research Roundtable (AARR); lead the Global Biomarker Standardization Consortium; manage and direct future meeting efforts and output; and assist with the coordination of the $100 million dollar Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study on the clinical usefulness of amyloid PET imaging. Before joining the Alzheimer’s Association, Dr. Hendrix was a pharmaceutical scientist with a focus on drug discovery for CNS diseases. Dr. Hendrix spent 18 years working at Sanofi-Aventis and predecessor companies, where he rose to level of senior director, U.S. site head for CNS research.